CRCL tops Q4 estimates as revenues jump 77% Y/Y, fueled by surging USDC circulation, soaring reserve income and sharply higher margins.

CRCL tops Q4 estimates as revenues jump 77% Y/Y, fueled by surging USDC circulation, soaring reserve income and sharply higher margins.

IART tops Q4 EPS and revenue estimates despite margin pressure and a sales dip, as shares edge higher and 2026 guidance signals modest growth.

IART tops Q4 EPS and revenue estimates despite margin pressure and a sales dip, as shares edge higher and 2026 guidance signals modest growth.

ALC's Q4 EPS and revenues lag estimates, sending shares down 3%, even as sales increase 9% and 2026 guidance targets up to 7% growth.

LKQ posts Q4 earnings miss as revenues slip year over year, though sales top estimates and 2026 guidance signals mixed growth outlook.

LKQ posts Q4 earnings miss as revenues slip year over year, though sales top estimates and 2026 guidance signals mixed growth outlook.

ORA posts Q4 earnings in line with estimates as revenues jump 19.6%, beats sales view and issues 2026 revenue guidance up to $1.16B.

KRYS beats Q4 estimates as Vyjuvek sales jump 17%. It secures 660+ U.S. reimbursements and advances the gene therapy pipeline into 2026.

KRYS beats Q4 estimates as Vyjuvek sales jump 17%. It secures 660+ U.S. reimbursements and advances the gene therapy pipeline into 2026.